🇺🇸 FDA
Pipeline program

TISAGENLECLEUCEL

CCTL019E2202

Phase 2 small_molecule active

Quick answer

TISAGENLECLEUCEL for Adult patients with refractory or relapsed follicular lymphoma is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
Adult patients with refractory or relapsed follicular lymphoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials